Brief: Seastar Medical Announces Completion Of FDA Enrollment Requirement For Save Surveillance Registry Evaluating Quelimmune Safety For Pediatric Aki
05/03/2026 13:24
March 5 (Reuters) - SeaStar Medical Holding Corp ICU.O: SEASTAR MEDICAL ANNOUNCES COMPLETION OF FDA ENROLLMENT REQUIREMENT FOR SAVE SURVEILLANCE REGISTRY EVALUATING QUELIMMUNE SAFETY FOR PEDIATRIC AKI Source text: ID:nGNX3RQzrM Further company coverage: ICU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsSeaStar Medical Q1 revenue rises on QUELIMMUNE growth
Brief: SeaStar Medical Q1 EPS USD -0.9
Brief: Seastar Medical Holding Corp - Prospectus Relates To Resale, From Time To Time, Of Up To 2 Million Shares Of Our Common Stock By Selling Stockholder
SeaStar Medical's Q4 revenue rises, net loss narrows
Brief: Seastar Medical Announces Completion Of FDA Enrollment Requirement For Save Surveillance Registry Evaluating Quelimmune Safety For Pediatric Aki